Sunday 18 October 2026
Export LCTX’s income statement to Excel — free account
Lineage Cell Therapeutics, Inc.
LCTX Healthcare Biotechnology
Lineage Cell Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.6 million, up 53.2% from fiscal 2024. In the quarter to June 2026, revenue fell 61.3%, EPS grew 104.8%, free cash flow fell 32.4% and total debt fell 68.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.98
0.01
−1.01%
Follow LCTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
24.98 | 26.20 | 26.40 | 35.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(45.12) | (47.93) | (78.78) | (106.96) | |
P/B ratio |
5.47 | 7.35 | 8.87 | 18.60 | |
Price to Tangible BV |
18.76 | 37.50 | 394.55 | 0.00 | |
EV/Sales |
21.10 | 22.59 | 22.57 | 32.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.59) | (15.10) | (17.37) | (16.99) | |
EV/FCF |
(11.32) | (14.78) | (16.90) | (16.59) | |
Quick Ratio |
6.44 | 6.65 | 4.99 | 4.33 | |
Current Ratio |
6.61 | 6.89 | 5.20 | 4.50 | |
Net Debt/EBITDA |
5.85 | 7.21 | 8.74 | 11.36 | |
Debt/Assets |
0.01% | 0.02% | 0.03% | 0.04% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.13 | 0.13 | 0.13 | 0.12 | |
Operating CF/Net income |
(4.89) | 1.68 | (5.73) | 0.12 | |
Capex/Depreciation |
(0.45) | (0.29) | (2.36) | (0.05) | |
Research and Development Expense of Revenue |
446.59% | 245.45% | 124.67% | 88.86% | |
Selling, General and Administrative Expense of Revenue |
488.12% | 294.72% | 73.43% | 113.85% | |
Intangible Assets out of Total Assets |
0.40 | 0.39 | 0.38 | 0.47 | |
Share Based Compensation of Revenue |
149.77% | 67.94% | 16.62% | 32.57% | |
Graham Net Nets |
0.02 | 0.00 | (0.03) | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.98%) | (17.72%) | (16.77%) | (17.16%) | |
Free Cash Flow Yield |
(7.46%) | (5.84%) | (5.06%) | (5.40%) | |
Revenue per Share |
0.00 | 0.01 | 0.03 | 0.02 | |
Operating CF per Share |
(0.03) | (0.03) | (0.02) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.03) | (0.02) | (0.02) | |
Cash per Share |
0.20 | 0.22 | 0.24 | 0.18 | |
Shareholders Equity per Share |
0.24 | 0.22 | 0.19 | 0.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.24 | 0.22 | 0.19 | 0.09 | |
Free Cash Flow |
(7.35) | (8.13) | (5.28) | (3.63) | |
Working Capital |
44.95 | 48.02 | 47.79 | 32.88 | |
Capital Expenditures |
(0.11) | (0.05) | (0.40) | (0.01) | |
Net Current Asset Value |
6.55 | (0.67) | (10.08) | (26.58) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.10 | 0.03 | 0.06 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.52 | 0.51 | 0.76 | 0.27 | |
Average Payables |
4.92 | 5.27 | 6.31 | 4.51 | |
Average Assets |
98.51 | 110.64 | 112.90 | 93.12 | |
Average Common Equity |
53.46 | 65.18 | 60.18 | 42.80 |
Columns are period end dates